SINOTAUPHARMA-B
| Register Close | 2026/11/19 IPO Closing in 3 Days |
| Listing Date | 2026/11/24 |
| Register Close | 2026/11/19 IPO Closing in 3 Days |
| Listing Date | 2026/11/24 |
Beijing Sinotau International Pharmaceutical Technology Co., Ltd. is a biotechnology company, dedicated to the development and commercialization of diagnostic and therapeutic radiopharmaceuticals with considerable market potential.
--
The Group's core business model involves the development and commercialization of radiopharmaceuticals in its strategically focused areas, namely oncology, neurodegenerative diseases and cardiovascular diseases.
--
The Group had developed a staggered, indication-oriented pipeline comprising 13 assets as of 21 October 2026, five of which were self-discovered and developed and three of which were self-developed, in each case by the Group. The Group's pipeline includes two Core Products, XTR008 and XTR004, as well as two Key Products, XTR003 and XTR006.
--
The Group's customers primarily comprise healthcare institutions and distributors that directly purchase pharmaceutical products and radionuclides from the Group, as well as pharmaceutical enterprises that purchase CRO or CDMO services from the Group. For Core Products, the Group held 25 registered patents, 23 of which are registered in China and two are registered in Japan, and 18 patent applications.
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 50 |
| No. of Offer Shares | 6.56M H shares |
| No. of International Offer Shares | 5.90M H shares |
| No. of HK Offer Shares | 0.66M H shares |
| Offer Price | $52.0 - $68.0 |
| Stock Code | 9941 |
| Sponsor(s) | GF Capital (Hong Kong) Limited, China International Capital Corporation Hong Kong Securities Limited, CITIC Securities (Hong Kong) Limited |
| Underwriter(s) | GF Securities (Hong Kong) Brokerage Limited, China International Capital Corporation Hong Kong Securities Limited, CLSA Limited, CMB International Capital Limited, DBS Asia Capital Limited, China Galaxy International Securities (Hong Kong) Co., Limited, BOCI Asia Limited, ABCI Securities Company Limited, Guolian Securities International Capital Co., Limited, BOCOM International Securities Limited, CMBC Securities Company Limited, Zheshang International Financial Holdings Co., Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited |
| Application Period | Nov 16 (Mon) - noon, Nov 19 (Thu) |
| Price Determination Date | Nov 20 (Fri) |
| Result Announcement Date | Not later than Nov 23 (Mon) |
| Result Announcement Date | On or before Nov 24 (Tue) |
| Result Announcement Date | On or before Nov 24 (Tue) |
| Dealings in Shares commence on | Nov 24, 2026. (Tue) |
| Offer Price | $52.0 - $68.0 |
| Capitalization | 3.41B - 4.46B |
| NAV / share ($) | $23.13 - $24.66 (Unaudited pro forma adj NAV / share) |
| Assuming the offer price being at HKD 60, the net proceeds raised would be HKD 329.10M, of which |
| 88% : Research, development and registrational filings of Core Product |
| 4.9% : Research and development of other product candidates |
| 1.1% : Reinforcement of sales and marketing capabilities |
| 1.1% : Construction of a new manufacturing facility in Tianjin |
| 5% : Working capital |
| Prospectus |
| Remark: | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |